Literature DB >> 30359964

Comprehensive Analysis of the Relationship Between RAS and RAF Mutations and MSI Status of Colorectal Cancer in Northeastern China.

Wenqi Li1, Huining Li2,3, Ruiqi Liu4, Xinxin Yang1, Yuhui Gao1, Yangyang Niu1, Jiashi Geng5, Yingwei Xue6, Xiaoming Jin3, Qi You6, Jingshu Geng1,3, Hongxue Meng7,8,9.   

Abstract

BACKGROUND/AIMS: Colorectal cancer (CRC) is mainly caused by chromosomal instability (CIN) and microsatellite instability (MSI). The RAS and RAF genes are essential components of the CIN pathway, and several studies have found that RAS and RAF mutations are associated with MSI status in CRC. Here, we examined these three factors in CRC in Northeast China and aimed to reveal new details of the relationship between these mutations and MSI status.
METHODS: This study involved 290 patients with CRC who had RAS or RAF gene mutation detected using fluorescence-based allele-specific polymerase chain reaction or Sanger sequencing. The majority of the identified patients were found to harbor MSI (MSI status). Accurate molecular detection was carried out using formalin-fixed paraffin-embedded tissue or blood samples.
RESULTS: The rates of RAS and RAF mutations were 58.5% and 4.1%, respectively. The prevalence of RAS mutation in CRC was clearly higher and that of RAF mutation was lower in Northeast China compared with previously reported cohorts in other locations. High MSI level (MSI-H status) was more complex, at around 10%. This was consistent with previous data from China. However, compared with data reported from other continents, MSI-H was higher than that of Japan or South Korea in Asia, and lower than that of Europe or the United States.
CONCLUSION: RAS/RAF mutations and MSI status in CRC are closely associated with tumor location and ethnicity. Further studies investigating the relationship between these three factors can help in the development of treatment strategies for patients with CRC.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Colorectal cancer; MSI; Northeastern China; RAF; Race; Ras

Mesh:

Substances:

Year:  2018        PMID: 30359964     DOI: 10.1159/000494649

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  6 in total

1.  Development of novel models for predicting mismatch repair protein deficiency and relevant disease-free survival in colorectal cancer patients.

Authors:  Yixin Xu; Yuzhe Li; Ziyan Zhu; Jing Yang; Yulin Tan; Yibo Wang; Xuezhong Xu
Journal:  Int J Colorectal Dis       Date:  2022-04-28       Impact factor: 2.571

2.  Incidence and detection of high microsatellite instability in colorectal cancer in a Chinese population: a meta-analysis.

Authors:  Congjun Zhang; Hongguang Ding; Shijun Sun; Zhonghua Luan; Guoyan Liu; Zhi Li
Journal:  J Gastrointest Oncol       Date:  2020-12

3.  Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.

Authors:  Chao Liu; Ruiqi Liu; Bojun Wang; Jie Lian; Yang Yao; Haoxiu Sun; Chunhui Zhang; Lin Fang; Xin Guan; Jiaqi Shi; Shuling Han; Fei Zhan; Shengnan Luo; Yuanfei Yao; Tongsen Zheng; Yanqiao Zhang
Journal:  J Immunother Cancer       Date:  2021-01       Impact factor: 13.751

4.  Analysis of the Clinicopathological Characteristics of Stage I-III Colorectal Cancer Patients Deficient in Mismatch Repair Proteins.

Authors:  Yichao Liang; Xinling Cai; Xu Zheng; Hongzhuan Yin
Journal:  Onco Targets Ther       Date:  2021-03-26       Impact factor: 4.147

5.  Mutation status and prognostic value of KRAS and NRAS mutations in Moroccan colon cancer patients: A first report.

Authors:  Fatima El Agy; Sanae El Bardai; Ihsane El Otmani; Zineb Benbrahim; Ibn Majdoub Hassani Karim; Khalid Mazaz; El Bachir Benjelloun; Abdelmalek Ousadden; Mohammed El Abkari; Sidi Adil Ibrahimi; Laila Chbani
Journal:  PLoS One       Date:  2021-03-30       Impact factor: 3.240

6.  Clinicopathological characteristics and mutational profile of KRAS and NRAS in Tunisian patients with sporadic colorectal cancer

Authors:  Donia Ounissi; Marwa Weslati; Rahma Boughriba; Meriam Hazgui; Saadia Bouraoui
Journal:  Turk J Med Sci       Date:  2021-02-26       Impact factor: 2.925

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.